1. Home
  2. HLF vs TSHA Comparison

HLF vs TSHA Comparison

Compare HLF & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Herbalife Ltd.

HLF

Herbalife Ltd.

HOLD

Current Price

$17.07

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$4.72

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HLF
TSHA
Founded
1980
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HLF
TSHA
Price
$17.07
$4.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
9
Target Price
$16.00
$10.56
AVG Volume (30 Days)
1.6M
2.8M
Earning Date
02-18-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
264.95
N/A
EPS
3.11
N/A
Revenue
$4,961,900,000.00
$6,310,000.00
Revenue This Year
$1.12
N/A
Revenue Next Year
$2.97
N/A
P/E Ratio
$5.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.04
$1.05
52 Week High
$17.67
$6.02

Technical Indicators

Market Signals
Indicator
HLF
TSHA
Relative Strength Index (RSI) 64.60 46.33
Support Level $16.40 $4.48
Resistance Level $17.60 $4.89
Average True Range (ATR) 0.68 0.28
MACD -0.05 -0.02
Stochastic Oscillator 61.84 40.90

Price Performance

Historical Comparison
HLF
TSHA

About HLF Herbalife Ltd.

Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management, targeted nutrition, Energy, Sports and Fitness, Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Latin America, EMEA, Asia Pacific regions, and China.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: